NCT04184700

Brief Summary

Lactobacillus GG (LGG) is able to exert long lasting effects in children with atopic disorders. Nutramigen LGG accelerates tolerance acquisition in infants with cow's milk allergy. The mechanisms of these effects are still largely undefined. The effect of LGG could be related at least in part by the immunoregulatory role played by LGG. This probiotic can balance the generation of cytokines possibly involved in IgE- or non-IgE-mediated cow's milk allergy Interleulkin (IL)-4, IL-5, IL-10, IFN-γ , TGF-β, and TNF-Υ), which can contribute to modulation of inflammatory processes. The investigators have demonstrated that children with IgE-mediated CMA produce significantly higher level of IL-4 and IL-13 in response to cow's milk protein, and that tolerance is associated with a marked reduction of IL-13 production and a concomitant increased frequency of IFN-γ releasing cells. Epigenetics studies the heritable (and potentially reversible) changes of the genome inherited from one cell generation to the next which alter gene expression but do not involve changes in primary DNA sequences, highlighting the complexity of the inter-relationship between genetics and nutrition. There are three distinct, but closely interacting, epigenetic mechanisms (histone acetylation, DNA methylation, and non-coding microRNAs) that are responsible for modifying the expression of critical genes associated with physiologic and pathologic processes. The profile of epigenetic modifications associated with Th lineage commitment, coupled with the sensitivity of the early developmental period, has led to speculation that factors that disrupt these pathways may increase the risk of allergic diseases. Specifically, effects on DNA methylation and endogenous histone deacetylase inhibitors acting on specific pathways (Th1 and T regulatory cell differentiation) may favour Th2-associated allergic differentiation. MicroRNAs are another structural components of an epigenetic mechanism of post-transcriptional regulation of messenger RNA translation. It has been recently identified a specific Th2-associated microRNA (miR-21) that is critical for the regulation of Th cell polarization. It has been previously demonstrated an inverse DNA methylation pattern of cytokines involved in Th2 response (IL-4, IL-5) compared with cytokines involved in Th1 response (IL-10, INF- y) in children with CMA acquiring oral tolerance, with the most pronounced effects in those treated with Nutramigen LGG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 29, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 3, 2019

Completed
7 days until next milestone

Study Start

First participant enrolled

December 10, 2019

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

April 14, 2026

Status Verified

December 1, 2025

Enrollment Period

4.1 years

First QC Date

November 29, 2019

Last Update Submit

April 9, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Epigenetic modifications in cytokines genes

    TSDR demethylation (prop.) of FOXP3 in children with cow's milk allergy. The primary outcome was the time-averaged FoxP3 Treg-Specific-Demethylation-Region (TSDR) demethylation (prop.), which took into account three repeated measures (0,6,12 months).

    12 months

Secondary Outcomes (7)

  • Epigenetic modifications in cytokines genes

    6 and 12 months

  • Epigenetic modifications in cytokines genes

    6 and 12 months

  • Epigenetic modifications in cytokines genes

    6 and 12 months

  • microRNAs modifications

    12 months

  • The rate of patients with immune tolerance acquisition to cow's milk protein

    12 months

  • +2 more secondary outcomes

Study Arms (5)

EHCF + LGG

EXPERIMENTAL

Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG

Dietary Supplement: EHCF+LGG

RHF

ACTIVE COMPARATOR

Extensively hydrolyzed rice formula

Dietary Supplement: RHF

EHWF

ACTIVE COMPARATOR

Extensively hydrolyzed protein formula

Dietary Supplement: EHWF

AAF

ACTIVE COMPARATOR

Amino acid based formula

Dietary Supplement: AAF

SF

ACTIVE COMPARATOR

Soy formula

Dietary Supplement: SF

Interventions

EHCF+LGGDIETARY_SUPPLEMENT

Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG

EHCF + LGG
RHFDIETARY_SUPPLEMENT

Rice hydrolysed formula

RHF
SFDIETARY_SUPPLEMENT

Soy formula

SF
EHWFDIETARY_SUPPLEMENT

extensively hydrolysed whey formula

EHWF
AAFDIETARY_SUPPLEMENT

amino acid based formula

AAF

Eligibility Criteria

Age6 Months - 12 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • children with cow's milk allergy

You may not qualify if:

  • Concomitant chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • autoimmune diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • malignancy,
  • chronic pulmonary diseases,
  • malformations of the gastrointestinal tract,
  • suspected eosinophilic esophagitis or eosinophilic enterocolitis,
  • suspected food-protein-induced enterocolitis syndrome,
  • suspected cow's milk protein-induced anaphylaxis,
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pediatric Office

Naples, 80100, Italy

Location

MeSH Terms

Conditions

Milk Hypersensitivity

Condition Hierarchy (Ancestors)

Food HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Full professor

Study Record Dates

First Submitted

November 29, 2019

First Posted

December 3, 2019

Study Start

December 10, 2019

Primary Completion

December 31, 2023

Study Completion

August 31, 2024

Last Updated

April 14, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations